File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Erlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung cancer
  • Basic View
  • Metadata View
  • XML View
TitleErlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung cancer
 
AuthorsWong, MK2
Lo, AI1
Lam, B2
Lam, WK2
Ip, MS2
Ho, JC2
 
KeywordsAsians
Disease control rate
Epidermal growth factor receptor tyrosine kinase inhibitors
Erlotinib
Gefitinib
Non-small cell lung cancer
 
Issue Date2010
 
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
 
CitationCancer Chemotherapy And Pharmacology, 2010, v. 65 n. 6, p. 1023-1028 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s00280-009-1107-5
 
AbstractPurpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. The purpose of this study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. Method Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as firstline treatment and subsequent salvage treatment with erlotinib. Results A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 12 (57.1%) patients with salvage erlotinib. There was an association between the disease control with gefitinib and erlotinib (p = 0.031). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. Conclusion For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib. © Springer-Verlag 2009.
 
ISSN0344-5704
2013 Impact Factor: 2.571
 
DOIhttp://dx.doi.org/10.1007/s00280-009-1107-5
 
PubMed Central IDPMC2946542
 
ISI Accession Number IDWOS:000275632400003
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorWong, MK
 
dc.contributor.authorLo, AI
 
dc.contributor.authorLam, B
 
dc.contributor.authorLam, WK
 
dc.contributor.authorIp, MS
 
dc.contributor.authorHo, JC
 
dc.date.accessioned2010-10-18T06:18:55Z
 
dc.date.available2010-10-18T06:18:55Z
 
dc.date.issued2010
 
dc.description.abstractPurpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. The purpose of this study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. Method Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as firstline treatment and subsequent salvage treatment with erlotinib. Results A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 12 (57.1%) patients with salvage erlotinib. There was an association between the disease control with gefitinib and erlotinib (p = 0.031). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. Conclusion For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib. © Springer-Verlag 2009.
 
dc.description.naturepublished_or_final_version
 
dc.description.otherSpringer Open Choice, 01 Dec 2010
 
dc.identifier.citationCancer Chemotherapy And Pharmacology, 2010, v. 65 n. 6, p. 1023-1028 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s00280-009-1107-5
 
dc.identifier.citeulike5541820
 
dc.identifier.doihttp://dx.doi.org/10.1007/s00280-009-1107-5
 
dc.identifier.eissn1432-0843
 
dc.identifier.epage1028
 
dc.identifier.hkuros172598
 
dc.identifier.isiWOS:000275632400003
 
dc.identifier.issn0344-5704
2013 Impact Factor: 2.571
 
dc.identifier.issue6
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC2946542
 
dc.identifier.pmid19680652
 
dc.identifier.scopuseid_2-s2.0-77951895524
 
dc.identifier.spage1023
 
dc.identifier.urihttp://hdl.handle.net/10722/123997
 
dc.identifier.volume65
 
dc.languageeng
 
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
 
dc.publisher.placeGermany
 
dc.relation.ispartofCancer Chemotherapy and Pharmacology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.rightsSpringer-Verlag
 
dc.subject.meshAged
 
dc.subject.meshCarcinoma, Non-Small-Cell Lung - drug therapy
 
dc.subject.meshLung Neoplasms - drug therapy
 
dc.subject.meshQuinazolines - therapeutic use
 
dc.subject.meshSalvage Therapy - methods
 
dc.subjectAsians
 
dc.subjectDisease control rate
 
dc.subjectEpidermal growth factor receptor tyrosine kinase inhibitors
 
dc.subjectErlotinib
 
dc.subjectGefitinib
 
dc.subjectNon-small cell lung cancer
 
dc.titleErlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung cancer
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Wong, MK</contributor.author>
<contributor.author>Lo, AI</contributor.author>
<contributor.author>Lam, B</contributor.author>
<contributor.author>Lam, WK</contributor.author>
<contributor.author>Ip, MS</contributor.author>
<contributor.author>Ho, JC</contributor.author>
<date.accessioned>2010-10-18T06:18:55Z</date.accessioned>
<date.available>2010-10-18T06:18:55Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Cancer Chemotherapy And Pharmacology, 2010, v. 65 n. 6, p. 1023-1028</identifier.citation>
<identifier.issn>0344-5704</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/123997</identifier.uri>
<description.abstract>Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. The purpose of this study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. Method Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as firstline treatment and subsequent salvage treatment with erlotinib. Results A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 12 (57.1%) patients with salvage erlotinib. There was an association between the disease control with gefitinib and erlotinib (p = 0.031). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. Conclusion For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib. &#169; Springer-Verlag 2009.</description.abstract>
<language>eng</language>
<publisher>Springer. The Journal&apos;s web site is located at http://www.springer.com/medicine/oncology/journal/280</publisher>
<relation.ispartof>Cancer Chemotherapy and Pharmacology</relation.ispartof>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<rights>Springer-Verlag</rights>
<subject>Asians</subject>
<subject>Disease control rate</subject>
<subject>Epidermal growth factor receptor tyrosine kinase inhibitors</subject>
<subject>Erlotinib</subject>
<subject>Gefitinib</subject>
<subject>Non-small cell lung cancer</subject>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Carcinoma, Non-Small-Cell Lung - drug therapy</subject.mesh>
<subject.mesh>Lung Neoplasms - drug therapy</subject.mesh>
<subject.mesh>Quinazolines - therapeutic use</subject.mesh>
<subject.mesh>Salvage Therapy - methods</subject.mesh>
<title>Erlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung cancer</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0344-5704&amp;volume=65&amp;issue=6&amp;spage=1023&amp;epage=1028&amp;date=2010&amp;atitle=Erlotinib+as+salvage+treatment+after+failure+to+first-line+gefitinib+in+non-small+cell+lung+cancer</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1007/s00280-009-1107-5</identifier.doi>
<identifier.pmid>19680652</identifier.pmid>
<identifier.pmcid>PMC2946542</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-77951895524</identifier.scopus>
<identifier.hkuros>172598</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77951895524&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>65</identifier.volume>
<identifier.issue>6</identifier.issue>
<identifier.spage>1023</identifier.spage>
<identifier.epage>1028</identifier.epage>
<identifier.eissn>1432-0843</identifier.eissn>
<identifier.isi>WOS:000275632400003</identifier.isi>
<publisher.place>Germany</publisher.place>
<description.other>Springer Open Choice, 01 Dec 2010</description.other>
<identifier.citeulike>5541820</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/123997/2/280_2009_Article_1107.pdf</bitstream.url>
</item>
Author Affiliations
  1. Centro Hospital Conde de Sao Januario
  2. The University of Hong Kong